Pregnenolone: 'Mother of All Hormones' for Burnout and Chronic Fatigue

Introduction: The Forgotten Hormone

Pregnenolone is a steroid hormone synthesized from cholesterol in the mitochondria of the adrenal cortex, gonads, and central nervous system. It is the starting precursor of absolutely all steroid hormones: DHEA, cortisol, aldosterone, testosterone, estradiol, and progesterone. This is why it is called the "mother of all hormones."

Despite its fundamental role, pregnenolone remains one of the least studied and prescribed hormones in clinical practice. Its levels begin declining at age 30, losing approximately 1-2% annually. By age 75, pregnenolone concentration is only 40% of the level at age 35 (Journal of Clinical Endocrinology & Metabolism, 2004).

Biosynthesis: From Cholesterol to the Steroid Cascade

Pregnenolone synthesis begins with cholesterol transport across the outer mitochondrial membrane by StAR protein (Steroidogenic Acute Regulatory protein). The enzyme CYP11A1 (P450scc) then cleaves the side chain of cholesterol, converting it to pregnenolone.

Pregnenolone then metabolizes through two main pathways: 1) the delta-5 pathway: pregnenolone to 17-OH-pregnenolone to DHEA to androstenedione to testosterone/estradiol; 2) the delta-4 pathway: pregnenolone to progesterone to 17-OH-progesterone to cortisol/aldosterone.

During chronic stress, the "pregnenolone steal" phenomenon occurs: the body redirects all available pregnenolone toward cortisol synthesis at the expense of DHEA, testosterone, and progesterone. This explains the characteristic hormonal profile in burnout: high cortisol with low DHEA, testosterone, and progesterone.

Pregnenolone as a Neurosteroid

Pregnenolone and its metabolites (pregnenolone sulfate, allopregnanolone) are among the most potent neurosteroids — substances synthesized directly in the brain that modulate neuronal activity.

Pregnenolone sulfate is a positive modulator of NMDA receptors, enhancing neuroplasticity, memory formation, and cognitive function. A study in PNAS (2013) showed that hippocampal pregnenolone sulfate levels correlate with working memory performance.

Allopregnanolone is a potent positive modulator of GABA-A receptors, possessing anxiolytic, sedative, and neuroprotective properties. Brexanolone (Zulresso), a synthetic allopregnanolone analogue, was FDA-approved in 2019 for postpartum depression — the first neurosteroid to receive regulatory approval.

Pregnenolone in Burnout and Chronic Fatigue

### The Neuroendocrinology of Burnout

Burnout is characterized by three stages of HPA axis dysregulation: 1) alarm stage — elevated cortisol and adrenaline; 2) resistance stage — cortisol normalizes but DHEA and pregnenolone decline; 3) exhaustion stage — low cortisol, low DHEA, low pregnenolone.

A systematic review in Psychoneuroendocrinology (2019) showed that the cortisol/DHEA ratio in burnout patients differs significantly from healthy controls. Pregnenolone, as the precursor of both, is a strategic intervention point.

### Clinical Evidence

A pilot study in Journal of Psychiatry & Neuroscience (2014): pregnenolone at 500 mg/day significantly improved cognitive function. Marx et al. (Psychopharmacology, 2009): 400 mg/day increased allopregnanolone levels by 200-300% and improved verbal memory.

When to Evaluate Pregnenolone

• Chronic fatigue not explained by other causes - Professional burnout with cognitive impairment ("brain fog") - Reduced stress resilience and emotional lability - Low DHEA with normal or elevated cortisol - Decreased libido combined with fatigue - Age-related cognitive decline

Diagnostic Testing

Serum Pregnenolone — morning fasting sample (8:00-10:00 AM). Reference ranges: males 22-237 ng/dL, females 11-204 ng/dL. Optimal: upper third of range. DHEA-Sulfate — mandatory alongside pregnenolone. Morning Cortisol — to assess HPA axis function. Expanded Steroid Panel (LC-MS/MS) — complete steroid metabolism picture.

Treatment Protocol

Dosing: - Starting dose: 5-15 mg/day in the morning (microdosing) - Standard burnout dose: 25-50 mg/day - Therapeutic (physician-supervised): 50-100 mg/day - Research doses: up to 500 mg/day (clinical settings only)

Formulations: micronized sublingual (best bioavailability), oral capsules, transdermal cream.

Duration: 8-12 weeks with lab reassessment. If positive response, continue 3-6 months. Not recommended beyond 6 months without hormonal monitoring.

Synergistic Agents

• Vitamin B5 (Pantothenic Acid): 500 mg/day — cofactor for steroidogenesis - Vitamin C: 1,000 mg/day — adrenal support - Magnesium Bisglycinate: 300-400 mg/day - Adaptogens: ashwagandha (300-600 mg KSM-66), rhodiola rosea (200-400 mg) - Phosphatidylserine: 100-300 mg/day — lowers evening cortisol

Safety

Contraindications: hormone-dependent tumors, pregnancy, lactation, severe liver disease. Side effects (at doses >100 mg/day): acne, irritability, insomnia, headache. Resolve with dose reduction. Drug interactions: caution with hormonal contraceptives, HRT, antiepileptic drugs.

Frequently Asked Questions

Is pregnenolone a hormone or a supplement? It is an endogenous steroid hormone. In the USA it is available OTC. In Europe a prescription may be required. Use under physician supervision with hormone monitoring.

Can pregnenolone increase testosterone? Yes, theoretically, through the metabolic cascade. However, conversion is unpredictable — depends on body needs. Monitoring is essential.

How does pregnenolone steal differ from adrenal insufficiency? Pregnenolone steal is functional redistribution, not organic damage. Addison's disease is autoimmune adrenal destruction with critically low cortisol.

Is pregnenolone suitable for women? Yes, considering menstrual cycle phase. Start in the luteal phase. In PCOS — caution due to possible androgen conversion.

*This article is for informational purposes only. Pregnenolone is a hormonal agent. Consultation with an endocrinologist and laboratory testing are mandatory before use.*

🌀

Differential Diagnosis: Ruling Out Non-HPA Causes of Chronic Fatigue

Chronic fatigue is a non-specific symptom. Before attributing it to pregnenolone insufficiency or HPA-axis dysregulation, several treatable conditions with overlapping presentations must be excluded. Misattribution delays definitive therapy and exposes patients to unnecessary hormone exposure.

Thyroid dysfunction. Both overt and subclinical hypothyroidism produce fatigue, cognitive slowing, cold intolerance, and weight gain that mimic adrenal burnout. A minimum panel includes TSH, free T4, free T3, and anti-TPO antibodies. Reverse T3 may be elevated in non-thyroidal illness syndrome and chronic stress states, complicating interpretation. In patients with TSH 2.5–4.5 mIU/L and persistent symptoms, free T3/reverse T3 ratio below 0.20 suggests impaired peripheral conversion rather than primary hypothyroidism.

Iron deficiency without anemia. Ferritin below 30 ng/mL with normal hemoglobin produces fatigue, exercise intolerance, and impaired cognition through reduced muscle myoglobin and mitochondrial cytochrome activity. Serum ferritin, transferrin saturation, and complete blood count are mandatory in any fatigue workup, particularly in menstruating women PMID: 24716182.

Vitamin B12 and folate deficiency. Serum B12 below 300 pg/mL warrants methylmalonic acid measurement, since cellular deficiency can occur with "normal-range" B12. Holotranscobalamin under 35 pmol/L is a more sensitive functional marker.

Sleep-disordered breathing. Obstructive sleep apnea elevates evening cortisol, blunts morning cortisol awakening response, and produces a clinical picture indistinguishable from HPA-axis dysregulation PMID: 19620710. A STOP-BANG score ≥3 or Epworth Sleepiness Scale >10 should prompt polysomnography before initiating hormonal therapy.

Chronic infections and post-viral syndromes. Epstein–Barr virus reactivation, chronic Lyme borreliosis, and post-acute sequelae of SARS-CoV-2 present with fatigue, cognitive fog, and post-exertional malaise. Reactivation EBV-EA IgG, CRP, and ESR should be screened when fatigue follows an identifiable infectious event.

Primary adrenal insufficiency (Addison disease). Morning cortisol below 5 µg/dL with elevated ACTH (>50 pg/mL) and an inadequate response to 250 µg cosyntropin (peak cortisol <18 µg/dL at 30 or 60 minutes) defines primary adrenal insufficiency. This requires glucocorticoid replacement, not pregnenolone, and missing the diagnosis is potentially fatal during intercurrent illness PMID: 25247841.

Depression and somatic anxiety. Major depressive disorder shares fatigue, anhedonia, and cognitive slowing with burnout. PHQ-9 and GAD-7 instruments should be applied in every fatigue assessment; scores ≥10 warrant psychiatric evaluation parallel to endocrine workup.

Mitochondrial dysfunction. Persistent fatigue with post-exertional malaise, elevated lactate, or elevated lactate-to-pyruvate ratio may indicate mitochondrial myopathy. Serum CK, lactate, and pyruvate provide a screening triad before subspecialty referral.

Only after these conditions are excluded — or being addressed in parallel — should pregnenolone deficiency be considered a primary driver of the fatigue phenotype.

🌀

Drug Interactions: Cytochrome P450 and Co-Prescribed Agents

Pregnenolone is metabolized through CYP17A1, CYP11A1, and 3β-HSD enzymatic steps. Several commonly co-prescribed agents alter steroidogenesis, hepatic clearance, or receptor occupancy, with clinically meaningful consequences.

Antiepileptic drugs. Carbamazepine, phenytoin, and phenobarbital are potent CYP3A4 and CYP2C9 inducers. They accelerate clearance of pregnenolone and its downstream metabolites, lowering circulating concentrations and reducing therapeutic effect. Valproate, in contrast, inhibits neurosteroid metabolism and may potentiate pregnenolone's GABAergic effects, increasing sedation risk. Dose titration should be slower in patients on enzyme-inducing antiepileptics, with serum pregnenolone reassessment after four weeks PMID: 22119571.

Hormonal contraceptives. Combined oral contraceptives elevate sex hormone-binding globulin and shift the delta-5 to delta-4 conversion balance. They suppress endogenous pregnenolone synthesis through ovarian and adrenal feedback. Exogenous pregnenolone in this context is more likely to convert toward DHEA-sulfate and testosterone, with potential androgenic effects. Lower starting doses (5–10 mg) are appropriate.

Glucocorticoids. Chronic prednisolone, dexamethasone, or hydrocortisone replacement suppresses ACTH-driven adrenal steroidogenesis, including pregnenolone synthesis. Patients on these agents have iatrogenically low pregnenolone, but supplementation does not bypass suppression of the broader HPA axis. Coordination with the prescribing physician is mandatory before adding pregnenolone, and abrupt discontinuation of glucocorticoids must not be attempted PMID: 28324636.

Selective serotonin reuptake inhibitors. Fluoxetine and sertraline elevate brain allopregnanolone concentrations independent of plasma pregnenolone, partly explaining their anxiolytic mechanism PMID: 9626712. Adding pregnenolone to an SSRI may produce additive GABAergic effects with sedation, paradoxical activation, or rarely, serotonergic interactions. Start at 5–10 mg and monitor mood for two weeks.

Aromatase inhibitors. Anastrozole and letrozole, used in breast cancer and male hypogonadism protocols, block conversion of androgens to estrogens. Exogenous pregnenolone may increase androgen substrate availability, requiring estradiol monitoring.

Statins. HMG-CoA reductase inhibition reduces cholesterol substrate for steroidogenesis. Some patients on high-dose statins develop reduced endogenous pregnenolone and DHEA. Pregnenolone supplementation is mechanistically rational in this subset but should be evidence-driven by measurement.

🌀

Hepatic and Renal Safety Monitoring

Although pregnenolone is generally well tolerated at physiological replacement doses, oral administration undergoes first-pass hepatic metabolism, and the contraindication for severe liver disease implies a monitoring obligation in all treated patients.

Baseline laboratory panel (before initiation). ALT, AST, GGT, alkaline phosphatase, total and direct bilirubin, albumin, complete blood count, creatinine with eGFR, urea, urinalysis, and lipid panel. Hepatitis B surface antigen and hepatitis C antibody screening are reasonable in patients with risk factors or unexplained transaminase elevation.

Follow-up testing. Repeat hepatic and renal panel at week 8 and again at month 6. Any elevation of ALT or AST greater than twice the upper limit of normal warrants temporary discontinuation, exclusion of other hepatotoxic exposures (alcohol, acetaminophen, supplements), and rechecking at four weeks. Persistent elevation contraindicates continued therapy PMID: 29325691.

Renal monitoring. Pregnenolone itself is not nephrotoxic, but downstream conversion to mineralocorticoid precursors can transiently affect sodium and potassium handling in susceptible patients. Serum sodium, potassium, and creatinine should be checked at baseline, week 8, and month 6, particularly in patients over 60 or those on diuretics, ACE inhibitors, or angiotensin receptor blockers.

Lipid response. Pregnenolone has a modest effect on total and LDL cholesterol through substrate shunting. In patients with baseline dyslipidemia, a fasting lipid panel at month 3 is prudent.

Hormonal cascade monitoring. Beyond hepatic and renal safety, downstream steroids should be measured at week 8: DHEA-sulfate, total and free testosterone, estradiol (in both sexes), and morning cortisol. Unintended elevations — particularly testosterone in women or estradiol in men — guide dose reduction or discontinuation.

Red-flag symptoms requiring immediate evaluation. Right upper quadrant pain, jaundice, dark urine, pruritus, persistent nausea, peripheral edema, or new hypertension demand pause and reassessment regardless of scheduled monitoring intervals.

🌀

Age- and Sex-Stratified Dosing Considerations

Endogenous pregnenolone declines approximately 1–2% annually after age 30, with steeper drops after age 50 in both sexes PMID: 12700375. However, age alone does not justify supplementation; clinical context, biochemistry, and symptom burden govern the decision. Stratification refines starting dose and target ranges.

Premenopausal women (age 20–45). Cyclical hormonal variation complicates interpretation. Baseline pregnenolone should be drawn in the early follicular phase (days 3–5) when steroid output is most stable. Starting dose: 5–10 mg in the luteal phase only, escalating cautiously. Avoid in women planning conception within three months — pregnenolone is contraindicated in pregnancy and exhibits a long tissue half-life. In polycystic ovary syndrome, the risk of androgenic conversion is elevated; baseline free testosterone and DHEA-sulfate measurement is mandatory before any supplementation PMID: 31091571.

Perimenopausal women (age 45–55). Erratic ovarian function combined with adrenal contribution to estrogen synthesis makes this group both highly symptomatic and biochemically variable. Starting dose 10–25 mg daily, with concurrent estradiol, progesterone, and FSH measurement to characterize ovarian reserve.

Postmenopausal women. Adrenal steroidogenesis becomes the dominant source of sex steroid precursors. Starting dose 25–50 mg, with attention to mammographic status and bone density. Pregnenolone is not a substitute for menopausal hormone therapy in women with vasomotor symptoms or established osteoporosis.

Men age 30–50. Conversion toward testosterone is variable but generally favorable in this cohort. Starting dose 10–25 mg, with baseline total testosterone, free testosterone, SHBG, and estradiol. Elevated estradiol (>40 pg/mL) at follow-up suggests aromatization and may require dose reduction.

Men age 50–70. Age-related decline in both pregnenolone and testosterone makes this group a common candidate for supplementation. Starting dose 25–50 mg. Prostate-specific antigen and digital rectal examination should be documented before initiation; PSA monitoring at month 3 and month 6 is appropriate, although pregnenolone has not been shown to accelerate prostate carcinogenesis at physiological doses PMID: 27448232.

Adults over 70. Cognitive complaints dominate the indication in this group. Starting dose 5–15 mg, with closer hepatic and renal monitoring given polypharmacy and age-related clearance changes. Higher doses provide no documented cognitive benefit and increase adverse event risk.

In all groups, the principle of "lowest effective dose for the shortest justified duration" supersedes any age-based template. Periodic reassessment every 8–12 weeks prevents indefinite therapy in patients whose clinical state has shifted.